STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit

STAT+ reports that Kyverna’s cell therapy demonstrated lasting autoimmune benefit, but the available excerpt is a paywalled teaser and does not include the underlying trial data, patient counts, or durability specifics.

The surrounding newsletter roundup also notes that an FDA advisory committee backed Grail’s cancer blood test and that Gilead is betting on autoimmune drug data, among other biotech news. It additionally references a new Theranos documentary and the possibility that Elizabeth Holmes could leave prison early.